RCT Data Needed on Phosphate-Lowering Agents and NDD-CKD Outcomes
Systematic reviews on this topic have largely been focused on patients receiving dialysis.
Hyperphosphatemia
Phosphate Binder Dissatisfaction May Affect Patient Outcomes
Dissatisfaction with taking phosphate binders may influence medication adherence and ultimately clinical outcomes, according to investigators.
FDA Wants Another Study Before Deciding on Tenapanor Approval
Tenapanor inhibits the sodium/hydrogen exchanger 3 to control serum phosphorus in adults with CKD on dialysis.
Tenapanor Monotherapy May Reduce Phosphorus Levels in Patients on Dialysis
Full results from the OPTIMIZE study, due to be completed in August 2021, are forthcoming.
Tenapanor Reduces Phosphate Binder Pill Burden in Hemodialysis
Unlike phosphate binders, tenapanor decreases paracellular phosphate absorption in the intestine.
In-Center Nocturnal Hemodialysis May Improve HRQOL
In a small Canadian study, investigators found that patients switched from conventional to in-center nocturnal hemodialysis experience improvements in various measures of health-related quality of life, especially mental health.
SHPT, Hyperphosphatemia Independently Linked With CKD Progression
Investigators ruled out hyperphosphatemia and SHPT as confounders in each other’s association with CKD outcomes.
Non-Calcium Phosphate Binder May Not Further Reduce Cardiovascular Events
Trial investigated lanthanum carbonate, which has been used worldwide to treat hyperphosphatemia and has been reported to delay vascular calcification.
Primary Failure of Arteriovenous Fistulas Linked to Elevated Phosphorus
Maintaining the patency of the AVF may be challenging in patients with hyperphosphatemia, study findings suggest.
Study IDs Most Effective Strategies to Reduce Fibroblast Growth Factor 23
Circulating FGF23 starts to rise in early stage CKD before the development of other abnormalities such as high parathyroid and phosphate levels and low calcium and 1,25(OH)2D levels.
- Loading...
Loading...
Next post in Secondary Hyperparathyroidism
Loading... 
Loading...